Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 3, 2010, Pages 371-378

  Żołnierek, Jakub ^a   Nurzyński, Pawel ^a   Langiewicz, Przemysław ^a   Oborska, Sylwia ^a   Waśko Grabowska, Anna ^a   Kuszatal, Ewa ^a   Obrocka, Beata ^a   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

IFN alfa; Metastasis; Renal cell carcinoma; Sorafenib tosylate; Sunitinib malate

Indexed keywords

ALPHA INTERFERON; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; PLACEBO; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMATITIS; TREATMENT RESPONSE; BONE TUMOR; COMPASSIONATE USE; DISEASE COURSE; DRUG DELIVERY SYSTEM; EVALUATION; KIDNEY TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BONE NEOPLASMS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMPASSIONATE USE TRIALS; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PLACEBOS; PYRIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77449133162     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0664-7     Document Type: Article

References (33)

1. TJ Abrams LB Lee LJ Murray NK Pryer JM Cherrington 2003 SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer Mol Cancer Ther 2 471 478 1:CAS:528: DC%2BD3sXkvVersbw%3D 12748309
2. M Beeram A Patnaik EK Rowinsky 2005 Raf: a strategic target for therapeutic development against cancer J Clin Oncol 23 6771 6790 10.1200/JCO.2005.08.036 1:CAS:528:DC%2BD2MXhtFWqsb7P 16170185 (Pubitemid 46194105)
3. R Bukowski C Szczylik W Stadler R Simantov M Shan 2007 Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis J Clin Oncol 25 18S 240s (Abstract 5023)
4. RE Coleman 1997 Skeletal complications of malignancy Cancer 80 1588 1594 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G 1:STN:280:DyaK1c%2Fis1Onuw%3D%3D 9362426
5. L Costa PP Major 2009 Effect of bisphosphonates on pain and quality of life in patients with bone metastases Nat Clin Pract Oncol 6 163 174 10.1038/ncponc1323 1:CAS:528:DC%2BD1MXisVSnsrg%3D 19190592
6. B Escudier C Szczylik T Eisen WM Stadler B Schwartz M Shan RM Bukowski 2005 Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) J Clin Oncol 23 16S 380s (Abstract LBA4510)
7. B Escudier T Eisen WM Stadler C Szczylik S Oudard M Siebels S Negrier C Chevreau E Solska AA Desai F Rolland T Demkow TE Hutson M Gore S Freeman B Schwartz M Shan R Simantov RM Bukowski 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D 17215530 (Pubitemid 46089673)
8. P Godley M Taylor 2001 Renal cell carcinoma Curr Opin Oncol 13 199 203 10.1097/00001622-200105000-00012 1:CAS:528:DC%2BD3MXjvVyjtbk%3D 11307065 (Pubitemid 32433978)
9. M Gore C Szczylik C Porta S Bracarda R Hawkins G Bjarnason S Oudard SH Lee J Haanen D Castellano E Vrdoljak P Schoffski P Mainwaring A Nieto J Yuan R Bukowski 2009 Safety and efficacy of sunitinib with subpopulation analysis in an expanded-access trial of metastatic renal cell carcinoma Lancet Oncol 10 757 763 10.1016/S1470-2045(09)70162-7 1:CAS:528:DC%2BD1MXptlalsrc%3D 19615940
10. NK Janzen HL Kim RA Figlin AS Belldegrun 2003 Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am 30 843 852 10.1016/S0094-0143(03)00056-9 14680319 (Pubitemid 37485197)
11. DW Kim YS Jo HS Jung HK Chung JH Song KC Park SH Park JH Hwang SY Rha GR Kweon SJ Lee KW Jo M Shong 2006 An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases J Clin Endocrinol Metab 91 4070 4076 10.1210/jc.2005-2845 1:CAS:528:DC%2BD28XhtFSjtbrN 16849418 (Pubitemid 44536887)
12. SL Kominsky M Doucet K Brady KL Weber 2007 TGF-β promotes the establishment of renal cell carcinoma bone metastasis J Bone Miner Res 21 37 44 10.1359/jbmr.061005 (Pubitemid 46032595)
13. W Lilleby SD Fossa 2005 Chemotherapy in metastatic renal cell cancer World J Urol 23 175 179 10.1007/s00345-004-0469-x 1:CAS:528:DC%2BD2MXmsFWmtbw%3D 15726382 (Pubitemid 41136038)
14. B Ljungberg D Hanbury M Kuczyk 2007 Renal cell carcinoma guideline Eur Urol 51 1502 1510 10.1016/j.eururo.2007.03.035 17408850 (Pubitemid 46634775)
15. DB Mendel AD Laird X Xin SG Louie JG Christensen G Li RE Schreck TJ Abrams TJ Ngai LB Lee LJ Murray J Carver E Chan KG Moss JO Haznedar J Sukbuntherng RA Blake L Sun C Tang T Miller S Shirazian G McMahon JM Cherrington 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 327 337 1:CAS:528:DC%2BD3sXnt1OrtA%3D%3D 12538485 (Pubitemid 36109749)
16. RJ Motzer NH Bander DM Nanus 1996 Renal-cell carcinoma N Engl J Med 335 865 875 10.1056/NEJM199609193351207 1:STN:280:DyaK28zlslajtA%3D%3D 8778606 (Pubitemid 26304070)
17. RJ Motzer BI Rini RM Bukowski BD Curti DJ George GR Hudes BG Redman KA Margolin JR Merchan G Wilding MS Ginsberg J Bacik ST Kim CM Baum MD Michaelson 2006 Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2516 2524 10.1001/jama.295.21.2516 1:CAS:528:DC%2BD28XlsV2rtLk%3D 16757724 (Pubitemid 43854967)
18. RJ Motzer TE Hutson P Tomczak MD Michaelson RM Bukowski O Rixe S Oudard S Negrier C Szczylik ST Kim I Chen PW Bycott CM Baum RA Figlin 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 17215529 (Pubitemid 46089672)
19. GR Mundy 2002 Metastasis to bone: causes, consequences and therapeutic opportunities Nature 2 584 593 1:CAS:528:DC%2BD38XlslGqsLo%3D
20. S Negrier B Escudier F Gomez JY Douillard A Ravaud C Chevreau M Buclon D Perol C Lasset 2002 Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie Ann Oncol 13 1460 1468 10.1093/annonc/ mdf257 1:STN:280:DC%2BD38vjvVGitA%3D%3D 12196373
21. AM O'Farrell TJ Abrams HA Yuen TJ Ngai SG Louie KW Yee LM Wong W Hong LB Lee A Town BD Smolich WC Manning LJ Murray MC Heinrich JM Cherrington 2003 SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 3597 3605 10.1182/blood-2002-07-2307 12531805 (Pubitemid 36857948)
22. JP Plastaras S-H Kim YY Liu DT Dicker JF Dorsey J McDonough G Cerniglia RR Rajendran A Gupta AK Rustgi JA Diehl CD Smith KT Flaherty WS El-Deiry 2007 Cell cycle-dependent and schedule-dependent antitumour effects of sorafenib combined with radiation Cancer Res 67 9443 9454 10.1158/0008-5472.CAN-07-1473 1:CAS:528:DC%2BD2sXhtFSnurvN 17909054 (Pubitemid 47535934)
23. MJ Ratain T Eisen WM Stadler KT Flaherty SB Kaye GL Rosner M Gore AA Desai A Patnaik HQ Xiong E Rowinsky JL Abbruzzese C Xia R Simantov B Schwartz PJ O'Dwyer 2006 Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505 2512 10.1200/JCO.2005.03.6723 1:CAS:528:DC%2BD28XmtVOmtrk%3D 16636341 (Pubitemid 46630627)
24. K Rohrmann M Staehler N Haseke A Bachmann CG Stief M Siebels 2005 Immunotherapy in metastatic renal cell carcinoma World J Urol 23 196 201 10.1007/s00345-004-0470-4 1:CAS:528:DC%2BD2MXmsFWmtb0%3D 15806434 (Pubitemid 41136042)
25. CW Ryan RM Bukowski R Figlin J Knox TE Hutson JP Dutcher J George J Kirshner J Humphrey WM Stadler On behalf of the ARCCS Investigators 2007 The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts) J Clin Oncol 25 18S 258s (Abstract 5096)
26. Sachdeva K, Makhoul I, Javeed M, Curti B (2008) Renal cell carcinoma. eMedicine http://www.emedicine.com/MED/topic2002.htm, 1-23
27. P Schoffski H Dumez P Clement A Hoeben H Prenen P Wolter S Joniau T Roskams PH Van 2006 Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review Ann Oncol 17 1185 1196 10.1093/annonc/mdj133 1:STN:280:DC%2BD28vkvVOltQ%3D%3D 16418310 (Pubitemid 44288208)
28. M Staehler N Haseke T Stadler A Karl CG Stief R Wilkowski 2009 Effectivity of radiation therapy in combination with multi-kinase inhibition based on sorafenib or sunitinib in progressive metastatic renal cancer Eur Urol Suppl 8 156 10.1016/S1569-9056(09)60149-4 (Abstract 143)
29. C Szczylik T Demkow M Staehler F Rolland S Negrier 2007 Randomized phase II trial of first line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results J Clin Oncol 25 18S 241s (Abstract 5025)
30. D Taussky D Soulières 2009 Hypofractionated radiotherapy with concomitant sunitinib-is there a radiosensitizing effect? Can J Urol 16 4599 4600 19364436
31. KL Weber M Doucet JE Price C Baker SJ Kim IJ Fidler 2003 Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice Cancer Res 63 2940 2947 1:CAS:528:DC%2BD3sXkt1ait7s%3D 12782601
32. S Wilhelm DS Chien 2002 BAY 43-9006: preclinical data Curr Pharm Des 8 2255 2257 10.2174/1381612023393026 1:CAS:528:DC%2BD38XnvVGntrs%3D 12369853 (Pubitemid 35189898)
33. J Zekri N Ahmed RE Coleman B Hancock 2001 The skeletal metastatic complications of renal cell carcinoma Int J Oncol 19 379 382 1:STN:280:DC%2BD3MzptFSmuw%3D%3D 11445855